Evidence map›Paper›PMID 21672195›Full record

ArticleRetrovirology2011

Human defensins 5 and 6 enhance HIV-1 infectivity through promoting HIV attachment.

Aprille Rapista, Jian Ding, Bernadette Benito, Yung-Tai Lo, Matthew B Neiditch, Wuyuan Lu, Theresa L Chang

Abstract read
In one paragraph

Article in Retrovirology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Peptide-Based Antiviral Drugs.Advances in experimental medicine and biology · 2021
    Article
  15. Article
  16. Antiviral Activities of Human Host Defense Peptides.Current medicinal chemistry · 2020
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aprille RapistaPublic Health Research Institute, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, NJ 07103, USA.
Jian Ding
Bernadette Benito
Yung-Tai Lo
Matthew B Neiditch
Wuyuan Lu
Theresa L Chang

Funding

Defensins in STI-Mediated Enhanced HIV InfectivityR01AI081559 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI CHANG, THERESA L · 2010 to 2014
$2.1M
Molecular Basis of Human Neutrophil alpha-Defensin FunctionR01AI061482 · NIAID · UNIVERSITY OF MD BIOTECHNOLOGY INSTITUTE · PI LU, WUYUAN · 2005 to 2009
$1.8M
NIAID NIH HHS AI061482NIAID NIH HHS AI081559NIAID NIH HHS R01 AI081559
6 · The paper itself

Abstract

backgroundConcurrent sexually transmitted infections (STIs) increase the likelihood of HIV transmission. The levels of defensins are frequently elevated in genital fluids from individuals with STIs. We have previously shown that human defensins 5 and 6 (HD5 and HD6) promote HIV entry and contribute to Neisseria gonorrhoeae-mediated enhancement of HIV infectivity in vitro. In this study, we dissect the molecular mechanism of the HIV enhancing effect of defensins.

resultsHD5 and HD6 primarily acted on the virion to promote HIV infection. Both HD5 and HD6 antagonized the anti-HIV activities of inhibitors of HIV entry (TAK 779) and fusion (T-20) when the inhibitors were present only during viral attachment; however, when these inhibitors were added back during viral infection they overrode the HIV enhancing effect of defensins. HD5 and HD6 enhanced HIV infectivity by promoting HIV attachment to target cells. Studies using fluorescent HIV containing Vpr-GFP indicated that these defensins enhanced HIV attachment by concentrating virus particles on the target cells. HD5 and HD6 blocked anti-HIV activities of soluble glycosaminoglycans including heparin, chondroitin sulfate, and dextran sulfate. However, heparin, at a high concentration, diminished the HIV enhancing effect of HD5, but not HD6. Additionally, the degree of the HIV enhancing effect of HD5, but not HD6, was increased in heparinase-treated cells. These results suggest that HD5 and haparin/heparan sulfate compete for binding to HIV.

conclusionsHD5 and HD6 increased HIV infectivity by concentrating virus on the target cells. These defensins may have a negative effect on the efficacy of microbicides, especially in the setting of STIs.

Indexed as

Virus Attachmentalpha-DefensinsHeLa CellsHIV-1HIV InfectionsHumansalpha-DefensinsDEFA5 protein, humanDEFA6 protein, human

Identifiers

PMID21672195
PMCPMC3146398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.